Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 38Carcinoma, Non-Small-Cell Lung 23Stomach Neoplasms 19Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 18Esophageal Squamous Cell Carcinoma 17Esophageal Neoplasms 16Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 8Sarcoma 6Recurrence 6Neoplasm Metastasis 6Melanoma 6Liver Neoplasms 6Cholangiocarcinoma 6Lung Neoplasms 5Hodgkin Disease 5Biliary Tract Neoplasms 5Osteosarcoma 4Neoplasms 4Locally Advanced Gastric Cancer 4Advanced Gastric Cancer 4Rectal Neoplasms 3Nasopharyngeal Neoplasms 3Glioblastoma 3Gestational Trophoblastic Disease 3Urinary Bladder Neoplasms 2

Interventions

HMPL-013 2toripalimab 1tislelizumab 1sintilimab 1regorafenib 1raltitrexed 1pembrolizumab 1camrelizumab 1Nivolumab 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Colorectal Carcinoma × camrelizumab × Clear all
NCT04771715 2021-02-25

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Peking Union Medical College Hospital

Unknown
100 enrolled
Gastrointestinal

Advanced Colorectal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡